Molecular Medicine Unit

What does the Unit treat?

At HM CIOCC, our Molecular Medicine Unit is dedicated to the molecular characterization of tumors to offer more precise and personalized oncological treatments. We have the most advanced technology and a team of experts to provide you with an accurate diagnosis and a treatment plan adapted to the unique characteristics of your tumor.

What makes us different?

• Advanced molecular diagnosis: We use the best diagnostic tests to characterize your tumor at a molecular level, both in tumor tissue and in liquid biopsy.
• Experience and knowledge: We have a team of experts in molecular medicine and oncology who interpret test results and translate them into personalized treatment plans.
• Leadership in innovation: We develop European-level reference tests for hyper-early oncological diagnosis.

Related Diseases

All types of cancer where molecular characterization can inform treatment decisions, including:

• Breast cancer.
• Lung cancer.
• Colon cancer.
• Melanoma.
• Leukemia.
• Lymphoma.

Who is it for?

• Cancer patients seeking personalized treatment options.
• Patients with a family history of cancer seeking risk assessment and early detection strategies.
• Oncologists seeking advanced diagnostic tools to guide treatment decisions.

What do we offer?

• Minimal residual disease test: Monitoring treatment response and detecting the presence of residual tumor cells to prevent relapse.
• Molecular targets in tumor tissue: Exhaustive analysis of the molecular characteristics of the tumor in tissue samples to identify the best treatment options.
• Molecular tests in liquid biopsy: Tumor monitoring through blood tests and other bodily fluids, allowing detection of changes and non-invasive adaptation of treatment.
• Hyper-early oncological diagnostic tests: Innovative tests for early cancer detection, allowing treatment to begin in the earliest stages of the disease.
• Predictive tests for treatment response: Identification of the most effective treatments for each patient, based on the molecular characteristics of their tumor.